Tag: shockwave medical
Shockwave IVL can aid in eliminating recoil and dissection during below-the-knee...
George Adams (Raleigh, USA) talks to VEITHtv at the VEITHsymposium 2019 (19–23 November, New York, USA) about the benefits of using easy-to-use Shockwave IVL (Intravascular Lithotripsy) in calcified...
Shockwave announces commercial availability of below-the-knew IVL catheter
Shockwave Medical today announced commercial availability of the Shockwave S4 peripheral intravascular lithotripsy (IVL) catheter in select approved geographies. Shockwave S4 is a low-profile...
Intra-arterial calcification poses “one of the biggest challenges” for endovascular therapy
Andrew Holden (Auckland, New Zealand) provides perspective on the first results from the Disrupt PAD III observational registry that were presented at the Charing...
Abiomed invests $15 million in Shockwave Medical
A press release reports that Abiomed is to invest US$15 million in Shockwave Medical and the two companies will collaborate on a training and...
Consider intravascular lithotripsy when treating calcified femoropopliteal arteries
Treating severely calcified arteries by endovascular means is still a challenge, although atherectomy, stents and lithotripsy are all techniques that are employed. Lithotripsy (also...
Novel approach in treating stenotic peripheral arteries shown to be safe...
Twelve-month data prove that intravascular lithotripsy; a novel approach using pulsatile sonic pressure waves to modify intimal and medium calcium in stenotic peripheral arteries,...
“Fantastic” live case demonstrates potential value of intravascular lithotripsy
In an exciting session at the Charing Cross Symposium (CX; 24-27 April, London, UK), the audience witnessed the demonstration of a novel treatment strategy...
Shockwave Medical announces US$35 million in new financing
Shockwave Medical has reported US$35 million in new financing, an extension of the company’s previously announced US$45 million Series C financing. New investor Fidelity Management...
Shockwave Medical reports positive results for Lithoplasty in calcified lesions below...
Shockwave Medical has reported positive results from the DISRUPT BTK Study, which were presented at the annual Cardiovascular and Interventional Radiological Society of Europe...
Shockwave Medical Lithoplasty system launched in USA as first patient enrolled...
Shockwave Medical has announced two milestones for its Lithoplasty system for the treatment of calcified plaque in patients with peripheral artery disease (PAD): enrolment...
Shockwave Medical appoints Doug Godshall as president and chief executive officer
Shockwave Medical has announced the appointment of Doug Godshall as president and chief executive officer.
Godshall was most recently the chief executive officer and a...
First US patient treated in vascular study of Shockwave Medical Lithoplasty...
PinnacleHealth CardioVascular Institute has enrolled the first US patient in a trial assessing the safety and effectiveness of a new type of approach for...
Shockwave Medical raises US$45 Million in Series C financing to advance...
Shockwave Medical has announced the closing of US$45 million in Series C financing led by Sectoral Asset Management, with participation from mutual funds advised...
Shockwave Medical announces plans for “largest ever” calcified peripheral artery disease...
Shockwave Medical has announced plans for DISRUPT PAD III—what is claims is the “largest ever” multicentre randomised study to exclusively enrol patients with calcified...
Six-month Shockwave Medical Disrupt PAD data show “consistent and predictable” procedural...
Shockwave Medical has announced positive clinical results from the pooled DISRUPT PAD Study, a single-arm, two-phase, multicentre study evaluating the safety and performance of...
Shockwave Medical Lithoplasty system is cleared by the FDA
Shockwave Medica has announced clearance from the US Food and Drug Administration (FDA) of the Lithoplasty system for the treatment of calcified plaque in...
